Comprehensive Pharmacotherapy Reference Guide
Guideline used: NCCN Clinical Practice Guidelines v1.2026 (April 2026)

DEFINITION

ALL is a malignancy of B- or T-lymphoid progenitor cells (lymphoblasts) characterised by uncontrolled proliferation and arrest of differentiation. Blasts replace the bone marrow and may infiltrate extramedullary sites (CNS, testes, lymph nodes, mediastinum).

EPIDEMIOLOGY

Parameter	Key Data
Annual US cases	~6,000–7,000 (ALL); bimodal peak: children <5 yrs & adults >50 yrs
Pediatric B-ALL	~85% of pediatric ALL; 5-yr OS >90% with modern regimens
AYA (15–39 yrs)	Less favorable cytogenetics vs. children; higher Ph+ incidence
Adult ALL	5-yr OS ~40–50%; drastically lower than pediatric due to comorbidities & worse biology
T-ALL	~15% of ALL; bimodal peak (children & young adults); associated with mediastinal mass

CLINICAL PRESENTATION

DIAGNOSIS (NCCN ALL-1)

Diagnostic criteria: Diagnosis requires bone marrow aspirate/biopsy demonstrating ≥20% lymphoblasts (immunophenotypically clonal). A clonal lymphoblast population of <20% may be considered ALL in appropriate clinical circumstances.

Test	Requirement	Clinical Relevance
Bone Marrow Aspirate + Biopsy	Required	H&E stain; ≥20% blasts; morphology classification
Immunophenotyping (Flow Cytometry)	Required	B- vs T-lineage, myeloid markers; aberrant antigen expression (CD10, CD19, CD20, CD34, TdT, CD3, CD7, etc.)
Cytogenetics (Conventional Karyotype)	Required	G-banded metaphase analysis for chromosomal abnormalities
FISH Panel	Required	BCR::ABL1, KMT2A, ETV6::RUNX1, MYC, others as indicated
RT-PCR for BCR::ABL1	Required	Distinguish p190 vs p210 transcript — critical for treatment & MRD monitoring
NGS (Comprehensive Fusion Panel)	Recommended	Detect Ph-like fusions (JAK-STAT, ABL-class), KMT2A partners, DUX4, MEF2D, ZNF384, others
MGPT (Multigene Panel Testing)	Recommended	Additional mutations; germline predisposition variants
CSF Analysis (LP)	Required at first IT therapy	CNS staging (CNS-1/2/3). Flow cytometry may be considered.
CBC with differential, CMP, LDH, Uric Acid	Required	Baseline; TLS risk assessment
Coagulation studies (PT, aPTT, fibrinogen, AT)	Required	DIC screen; baseline before asparaginase
Echocardiogram or MUGA	Required	Baseline cardiac function before anthracyclines
HLA typing	Strongly consider	Early donor search for transplant-eligible patients
CT/MRI head with contrast	If neuro symptoms	Rule out CNS bleeding, chloroma, meningeal disease
PET/CT (whole body preferred)	If lymphomatous involvement suspected/confirmed by CT	Updated NCCN v1.2026 recommendation
Pregnancy test (females of childbearing age)	Required	Before initiating chemotherapy
HIV, Hepatitis B/C serology	Required	Infection screen; HBV reactivation risk with rituximab
Germline predisposition testing	Recommended	Especially prior to allogeneic HCT; impacts donor/regimen selection

Immunophenotyping Key Markers

Lineage	Positive Markers	Negative Markers / Notes
B-ALL	CD19, CD22, CD79a, PAX5, TdT, CD34 (variable), CD10 (common)	CD10 NEGATIVE → correlates with KMT2A rearrangement. CD20 positivity (>20% blasts) has therapeutic implications (rituximab)
T-ALL	CD3 (cytoplasmic or surface), CD7, CD2, CD5, CD4/CD8, TdT	ETP-ALL: CD5 dim/negative, CD1a negative, CD34 positive/negative, stem cell markers + myeloid markers
MPAL	Co-expression of lymphoid + myeloid markers meeting WHO/ICC threshold	Requires expert hematopathology review; separate treatment algorithm

CNS STAGING & EXTRAMEDULLARY DISEASE (NCCN ALL-B)

CNS Classification

CNS Status	Definition	Clinical Implications
CNS-1	No blasts on cytocentrifuge of CSF	Standard CNS prophylaxis only
CNS-2	<5 WBC/µL with blasts on cytocentrifuge (non-traumatic LP), OR traumatic LP with blasts	Intensified IT therapy; higher-risk classification
CNS-3	≥5 WBC/µL with blasts OR cranial nerve palsy	Active CNS disease — requires treatment-intensity IT + systemic therapy adjustment
Traumatic LP	RBC present; presence of blasts unclear	Assess blasts:RBC ratio; repeat LP may be needed; some protocols upstage

Extramedullary Sites & Management

• CNS: IT therapy (methotrexate ± cytarabine ± corticosteroid). Cranial irradiation largely replaced by IT + systemic therapy.
• Testes: Testicular radiation (involved site) if bilateral involvement or failure to respond to systemic therapy.
• Mediastinum (T-ALL): Responds to systemic therapy; steroids for rapid cytoreduction if airway compromise.
• Lymph nodes/liver/spleen: Generally respond to systemic chemotherapy; PET/CT for assessment.

CYTOGENETICS & MOLECULAR RISK STRATIFICATION (NCCN ALL-2)

B-ALL Risk Groups

Risk Group	Cytogenetic/Molecular Alterations
Standard Risk	Hyperdiploidy (51–65 chr) — best if trisomy 4, 10, 17 t(12;21) ETV6::RUNX1 t(1;19) TCF3::PBX1 DUX4 rearranged PAX5 P80R BCR::ABL1 WITHOUT IKZF1plus and without antecedent CML	Favorable prognosis; chemotherapy ± TKI (Ph+) ETV6::RUNX1 is CRYPTIC — needs FISH/PCR BCR::ABL1 alone (no IKZF1plus, no prior CML) = standard risk
Poor Risk	Hypodiploidy (<44 chr):   – Low hypodiploidy (30–39 chr)   – Near triploidy (60–78 chr) TP53 mutation KMT2A rearranged (t[4;11] or others) IgH rearrangements (incl. IGH::IL3) HLF rearranged ZNF384 rearranged MEF2D rearranged MYC rearranged Ph-like (BCR::ABL1-like) ALL:   – JAK-STAT (CRLF2r, EPORr, JAK1/2/3r, TYK2r, SH2B3, IL7R)   – ABL class (ABL1, ABL2, PDGFRA, PDGFRB, FGFR)   – Other (NTRK1/2/3r, FLT3r, LYNr, PTK2Br) PAX5alt BCR::ABL1 WITH IKZF1plus and/or antecedent CML iAMP21 IKZF1 alterations (alone or as IKZF1plus) Complex karyotype (≥5 abnormalities)	Poor prognosis; strong consideration for allogeneic HCT in CR1 IKZF1plus = IKZF1 deletion + CDKN2A/B, PAX5, or other co-deletions → very high risk Ph-like ALL: targetable kinase fusions; JAK-STAT → consider JAK inhibitors; ABL-class → TKI therapy KMT2A t(4;11): very poor prognosis; often CD10-negative Near-haploidy/low hypodiploidy may appear hyperdiploid on flow cytometry (doubled chromosomes) — verify by SNP array

T-ALL Risk Features

• No universally standardized risk stratification system for T-ALL (unlike B-ALL).
• ETP-ALL: Worst prognosis subset. Markers: CD5 dim/negative, CD1a negative, CD34+/−, myeloid/stem cell markers.
• Non-ETP T-ALL: Better outcomes. Cortical T-ALL (CD1a+, CD4/CD8 double positive) has best prognosis within T-ALL.
• MRD positivity after induction is the strongest prognostic marker for relapse.
• NOTCH1/FBXW7 mutations: favorable; PTEN/RAS/PI3K mutations: worse prognosis.

Adult Risk Stratification Parameters

• High WBC (≥30×10⁹/L for B-ALL; ≥100×10⁹/L for T-ALL): traditional risk factor but may lose independent significance when cytogenetics + MRD are considered.
• Age ≥35 yrs: generally associated with worse outcomes in adults.
• Patients ≥65 years or with substantial comorbidities: classified/managed separately — reduced-intensity regimens.
• MRD status post-induction: strongest independent predictor of outcome regardless of other risk factors.

DIFFERENTIAL DIAGNOSIS

Diagnosis	Key Distinguishing Features	How to Differentiate from ALL
AML (Acute Myeloid Leukemia)	Myeloid blasts; Auer rods	Flow cytometry: MPO+, CD33+, CD117+; TdT usually negative; no lymphoid markers
MPAL (Mixed Phenotype Acute Leukemia)	Meets criteria for both lymphoid + myeloid	WHO/ICC criteria; requires expert review; treated differently
Burkitt Leukemia/Lymphoma (B-ALL with MYC)	High-grade B-cell; >25% blasts in BM; MYC translocation	Mature B-cell (sIg+, TdT−); distinct morphology; requires specific R-CODOX-M/R-IVAC regimen
CML Blast Phase	BCR::ABL1+; prior CML history or evidence of CP/AP CML	p210 transcript; check for chronic phase features; treated as Ph+ ALL but different goals
Lymphoblastic Lymphoma (LL)	<25% blasts in bone marrow; predominantly nodal/mediastinal	Same biology as ALL — treated with ALL regimens; CNS prophylaxis same principles
Aplastic Anemia	Pancytopenia without blasts	BM biopsy: hypocellular without blasts
Viral/EBV infectious lymphocytosis	Reactive lymphocytes	Flow cytometry: polyclonal; self-limiting; no blasts
Myelodysplastic Syndrome	Cytopenias with dysplasia	BM dysplastic features; chromosomal analysis; rarely >20% blasts

TREATMENT PHASES

	Induction	Consolidation	Maintenance
Goal	Achieve complete remission (CR) and MRD negativity	Eliminate residual disease/MRD; reduce relapse	Long-term disease control; reduce late relapse
Duration	4–8 weeks	Several months (cycles)	2–3 years
Key Components	Corticosteroids, vincristine, asparaginase, anthracycline ± TKI (Ph+). IT chemotherapy throughout.	High-dose methotrexate, cytarabine, asparaginase, anthracyclines, cyclophosphamide, vincristine ± blinatumomab (Ph+/Ph-) ± TKI	Daily 6-MP, weekly MTX, monthly vincristine + prednisone pulses ± TKI (Ph+)

Ph+ B-ALL TREATMENT (NCCN ALL-4 | ALL-D 5–8 of 29)

Induction — Ph+ B-ALL

NCCN Recommendation: Clinical trial (PREFERRED) OR Systemic therapy + TKI

AYA and Adults <65 yrs Without Substantial Comorbidities — Frontline

Category	Regimens
Preferred	– Clinical trial – HyperCVAD + TKI (dasatinib preferred over imatinib) – Pediatric-inspired regimen (CALGB 10403 modification) + TKI
Other Recommended (High Intensity)	– Multiagent induction + TKI (BFM-based) – COG AALL0031-based regimen + TKI
Other Recommended (Moderate Intensity)	– ECOG/MRC/MDACC-based regimens + TKI – DA-EPOCH + TKI (Category 2B, added v1.2026) – PhALLCON Regimen + TKI (added v1.2026) – Steroids + TKI (low-intensity option for frail/elderly-like patients)

Adults ≥65 yrs or Substantial Comorbidities — Frontline

• Steroids + TKI (prednisone/dexamethasone + dasatinib/ponatinib/nilotinib)
• Moderate intensity multiagent regimens + TKI
• Dose-adjusted EPOCH + TKI (Category 2B, v1.2026 addition)
• PhALLCON Regimen + TKI (v1.2026 addition)
• Consider allogeneic HCT in appropriate fit individuals achieving remission (updated v1.2026)

BCR::ABL1 Inhibition Selection — Ph+ B-ALL (NCCN ALL-D 1–2 of 29)

TKI	Generation	Key Notes for Ph+ ALL
Imatinib	1st gen	RESTRICTED to patients who cannot tolerate broader-acting TKIs (per updated v1.2026). Narrow mutation coverage.
Dasatinib	2nd gen	Preferred for first-line (broad BCR::ABL1 coverage; CNS penetration). 100 mg daily (typical ALL dose). Watch: pleural effusion, QTc prolongation, thrombocytopenia.
Nilotinib	2nd gen	Less CNS penetration. Risk: QTc prolongation, pancreatitis. Avoid with strong CYP3A4 inhibitors.
Bosutinib	2nd gen	Limited data in Ph+ ALL specifically (NCCN notes). GI toxicity profile.
Ponatinib	3rd gen	Active against T315I mutation. High potency. Risk: arterial occlusive events, pancreatitis. Dose-adjusted based on response (starting 30–45 mg → reduce to 15 mg for MRD negativity).
Asciminib	STAMP inhibitor	Category 2B, useful in certain circumstances — for patients with intolerance/ contraindication to multiple other TKIs. Can be used ± another TKI.

ABL1 Kinase Domain Mutation Testing

• Perform at: baseline (induction), MRD+ after induction, less than marrow CR, persistent/progressive/emergent MRD, and before switching TKI.
• Note: ABL1 KD mutation testing may be LESS SENSITIVE with minimal disease burden — interpret with caution.
• T315I mutation: ONLY sensitive to ponatinib or asciminib.
• E255K/V, F359V: more resistant to dasatinib — switch to ponatinib.
• Y253H, E255K/V: resistant to nilotinib — switch accordingly.

Dose-Adjusted EPOCH

Levels	-2 (64%)	-1 (80%)	1 (100%)	2 (120%)	3 (144%)	4 (173%)	5 (207%)	6 (248%)
Etoposide (mg/m2/day) D1-4	50	50	50	60	72	86	104	124
Doxorubicin (mg/m2/day) D1-4	10	10	10	12	14.4	17.3	20.7	24.8
Cyclophosphamide (mg/m2/day) D5	480	600	750	900	1080	1296	1555	1866

Consolidation — Ph+ B-ALL

MRD Status Post-Induction	NCCN Recommended Consolidation
MRD Positive	Blinatumomab + TKI (PREFERRED — especially for MRD+ and those not previously on blinatumomab) OR Multiagent therapy + TKI (can continue induction if MRD declining; change if MRD+ >3 months) OR Allogeneic HCT in appropriate candidates
MRD Negative	Blinatumomab + TKI (preferred, still recommended) OR Continue multiagent therapy + TKI OR TKI alone (rare; seldom effective alone) OR Allogeneic HCT in appropriate candidates
Post-HCT	TKI maintenance (post-HCT TKI maintenance standard) Consider allogeneic HCT + post-HCT TKI when feasible

Maintenance — Ph+ B-ALL

• TKI maintenance (preferred for those not proceeding to HCT).
• May include: vincristine, corticosteroids, IT therapy in addition to TKI.
• Duration: typically 2–3 years total therapy duration (protocol-specific).

Ph− B-ALL TREATMENT (NCCN ALL-5 | ALL-D 10–15 of 29)

Induction — Ph− B-ALL (AYA & Adults)

Category (AYA/Adults <65 yrs)	Regimens
Preferred	Clinical trial Pediatric-inspired regimens (e.g., CALGB 10403, DFCI, COG-based for AYA) HyperCVAD (MD Anderson)
Other Recommended (High Intensity)	Linker 4-drug regimen BFM-based multiagent regimens
Other Recommended (Moderate)	Modified BFM with liposomal cytarabine for older adults
CD20+ B-ALL	Add rituximab to induction/consolidation (CD20 >20%)

HyperCVAD Regimen — Key Pharmacotherapy Details

Cycle Type	Drugs	Standard Doses
Odd cycles (A): 1,3,5,7	Hyperfractionated Cyclophosphamide Vincristine Doxorubicin (Adriamycin) Dexamethasone	Cyclophosphamide 300 mg/m² IV q12h × 6 doses (days 1–3) Vincristine 2 mg IV days 4, 11 Doxorubicin 50 mg/m² IV day 4 Dexamethasone 40 mg PO/IV days 1–4, 11–14
Even cycles (B): 2,4,6,8	High-dose Methotrexate Cytarabine	Methotrexate 1 g/m² IV over 24h day 1 (with leucovorin rescue) Cytarabine 3 g/m² IV q12h × 4 doses days 2–3 (1 g/m² if age >60 or CrCl issues)
IT therapy	IT methotrexate and/or cytarabine	IT MTX 12 mg + IT Ara-C 100 mg each cycle; total CNS prophylaxis per protocol

CALGB 10403 (Pediatric-Inspired) — Key Features

• AYA population (ages 17–39). 5-yr OS ~73% vs ~46% with adult regimens (major trial).
• Includes pegaspargase (core component), not in traditional adult regimens.
• Induction: prednisone, vincristine, daunorubicin, pegaspargase + IT methotrexate.
• Consolidation: high-dose MTX, MP, 6-MP, IT therapy.
• Maintenance: 6-MP daily, MTX weekly, vincristine/prednisone monthly pulses × 2 years.

Rituximab in CD20+ Ph− B-ALL

• GRAALL-2005 trial: Rituximab 375 mg/m² added to induction/consolidation in CD20+ (>20%) Ph− B-ALL → significantly improved event-free survival in adults ≤60 yrs.
• NCCN: addition of rituximab should be considered in CD20-positive (>20% of blasts) B-ALL.
• Dose: 375 mg/m² IV, timing per protocol. Premedication: acetaminophen + diphenhydramine.
• Monitor: HBV reactivation (screen all patients; prophylaxis with entecavir if HBsAg+ or anti-HBc+ with low anti-HBs).

Consolidation — Ph− B-ALL

• Continuation of multiagent chemotherapy (high-dose MTX, ara-C, asparaginase, cyclophosphamide-based).
• Blinatumomab: may be incorporated for MRD+ disease (data from BLAST trial and others).
• Inotuzumab ozogamicin (InO): primarily relapsed/refractory setting; can be used as bridge to HCT.
• Allogeneic HCT: strongly favored for poor-risk cytogenetics and/or MRD positivity post-consolidation.

Maintenance — Ph− B-ALL

Drug	Standard Dose	Duration	Monitoring
6-Mercaptopurine (6-MP)	50–75 mg/m² PO daily (adjust to target ANC 1.5–3.0×10⁹/L)	2–3 years total (per protocol)	CBC weekly initially → q2-4 weeks; LFTs; TPMT/NUDT15 genotype before starting
Methotrexate (oral)	20 mg/m² PO weekly	2–3 years	CBC, LFTs; hold for oral mucositis; hold if significant transaminase elevation
Vincristine	1.5 mg/m² IV (2 mg cap) monthly	2 years (per protocol)	Neuropathy assessment; constipation prophylaxis (stool softeners/bowel regimen)
Prednisone/Dexamethasone	Prednisone 40 mg/m²/day (or dex equivalent) × 5 days monthly	2 years (per protocol)	Blood glucose, BP, bone density (long-term); GI prophylaxis (PPI)

T-ALL TREATMENT (NCCN ALL-6 | ALL-D 17–22 of 29)

Induction — T-ALL (AYA & Adults)

Category	Regimen
Preferred	Clinical trial Pediatric-inspired regimens (AYA) HyperCVAD (adults)
Other Recommended	ECOG-based multiagent regimens Nelarabine-containing regimens (T-ALL specific — category 2B for frontline; preferred in relapse)
Nelarabine Addition	Nelarabine 650 mg/m²/day IV days 1–5 (pediatric inspired) or protocol-specific dosing. Addition to standard induction/consolidation; associated with improved OS in some T-ALL subsets.

Nelarabine — Key Pharmacotherapy

• MOA: Prodrug of 9-β-D-arabinofuranosylguanine (ara-G) — T-cell selective due to high expression of deoxyguanosine kinase.
• Dose: Adults 1500 mg/m² IV over 2h on days 1, 3, 5 (q21 days). Pediatric: 650 mg/m²/day × 5 consecutive days.
• CNS toxicity: Major concern — somnolence, confusion, seizures, peripheral neuropathy, ascending neuropathy (Guillain-Barré-like syndrome). Hold for neurotoxicity Grade ≥2.
• NEVER administer intrathecally.
• Myelosuppression: Monitor CBC closely.
• Adequate hydration required.

Consolidation — T-ALL

• Continuation multiagent chemotherapy with T-ALL specific intensification.
• Nelarabine: incorporated in some consolidation cycles.
• Allogeneic HCT: Strongly considered for ETP-ALL, MRD+ post-induction, relapsed disease.
• No approved targeted agents specific for T-ALL frontline (unlike B-ALL with blinatumomab/InO).

Maintenance — T-ALL

• 6-MP 75 mg/m² PO daily + oral MTX 20 mg/m² weekly.
• Monthly vincristine + prednisone pulses.
• Nelarabine may be incorporated (protocol-specific).
• CNS prophylaxis continues throughout.

RELAPSED / REFRACTORY ALL (NCCN ALL-8 | ALL-D 24–29 of 29)

Relapsed/Refractory Ph+ B-ALL

Category	Options
Preferred	Clinical trial Blinatumomab ± TKI Ponatinib-based regimen (especially T315I mutation) Asciminib +/- TKI (if multiple TKI intolerance, Cat 2B)
Other Recommended	HyperCVAD + TKI (switch TKI based on mutation profile) MOpAD regimen + TKI ± rituximab (CD20+) Steroids + TKI CAR T-cell therapy (if eligible) Allogeneic HCT after salvage CR
Post-Salvage	Allogeneic HCT preferred if CR2 achieved

Relapsed/Refractory Ph− B-ALL

Agent/Regimen	Class/MOA	Key Notes
Blinatumomab (BLINCYTO®)	BiTE (CD19×CD3 bispecific T-cell engager)	Preferred in R/R B-ALL. 28-day continuous IV infusion via pump. CRS management crucial. Cytoreduction if blasts ≥15,000/µL. See toxicity section.
Inotuzumab Ozogamicin (Besylomi®)	Anti-CD22 ADC (calicheamicin payload)	SOS/VOD risk — critical pre-HCT consideration. Avoid double-alkylator conditioning. Monitor LFTs/bilirubin.
Tisagenlecleucel (Kymriah®)	CD19-directed CAR T-cell	Ages ≤25 yrs (FDA-approved). 1-time infusion. CRS, ICANS, cytopenia management. Lymphodepletion (fludarabine + cyclophosphamide) required.
Brexucabtagene Autoleucel (Tecartus®)	CD19-directed CAR T-cell	Adults with R/R B-ALL. 1-time infusion after lymphodepletion. CRS, ICANS risk.
Obecabtagene Autoleucel (Aucatzyl®)	CD19-directed CAR T-cell	Adults with R/R B-ALL. 1-time infusion. Added to NCCN as option.
Augmented HyperCVAD	Intensified chemotherapy	Intensified vincristine, pegaspargase, dexamethasone alternating with HD MTX/Ara-C
Clofarabine ± combinations	Purine nucleoside analog	Monitor LFTs closely; hepatotoxicity; myelosuppression. Intensive supportive care required.
FLAG-IDA	Fludarabine, cytarabine, G-CSF ± idarubicin	MRD monitoring essential; bridging to HCT
Revumenib	KMT2A/menin inhibitor	KMT2A-rearranged ALL; differentiation syndrome monitoring
Venetoclax combinations	BCL-2 inhibitor	mini-hyperCVD + venetoclax; azacitidine + venetoclax; emerging data in R/R Ph-negative B-ALL

Relapsed/Refractory T-ALL

• PREFERRED: Clinical trial.
• Nelarabine ± etoposide/cyclophosphamide (key agent in R/R T-ALL).
• High-dose cytarabine-containing regimens.
• Venetoclax-containing regimens (nelarabine + venetoclax; mini-hyperCVD + venetoclax; HMA + venetoclax).
• Daratumumab-containing regimen (category 2B; targets CD38 expression in T-ALL).
• Revumenib: KMT2A-rearranged T-ALL.
• Bortezomib-containing regimen.
• MOpAD regimen (late relapse >3 yrs from initial diagnosis: consider same initial regimen).
• FLAG-IDA, clofarabine ± cyclophosphamide/etoposide

KEY AGENTS — DOSING, MONITORING & PHARMACIST WATCHOUTS

Blinatumomab (BLINCYTO®)

Parameter	Details
MOA	BiTE antibody: binds CD19 (B-cell) and CD3 (T-cell) simultaneously → T-cell cytotoxicity against B blasts
Indication	R/R B-ALL (adults & peds ≥1 yr); MRD+ B-ALL; Ph+ consolidation (+ TKI)
Dose — R/R B-ALL	Induction cycle 1: 9 mcg/day × 7 days, then 28 mcg/day × 21 days (28-day continuous IV infusion). Subsequent cycles: 28 mcg/day × 28 days. Consolidation: 28 mcg/day × 28 days.
Dose — MRD+ (Ph+ consolidation)	28 mcg/day continuous IV infusion × 28 days per cycle
Administration	Continuous IV infusion via ambulatory pump. Must use IV bag with specific stabilizer. Change bags per pharmacy/manufacturer instructions (every 24–96h depending on concentration).
Premedication	Dexamethasone 20 mg IV 1h prior to first dose of cycle and prior to step-up dosing (day 8 in cycle 1)
Cytoreduction threshold	Cytoreduction if blasts ≥15,000/µL before starting blinatumomab
CRS Management	Interrupt infusion; steroids; consider tocilizumab for severe CRS. Restart at reduced rate after resolution.
Neurological toxicity	Hold for Grade ≥3 neurological events; restart at 9 mcg/day after ≥7 days resolution.
Down syndrome	NEW v1.2026: Increased seizure risk — consider antiepileptic prophylaxis (e.g., levetiracetam).
Key Labs	CBC, LFTs, BMP, neurological assessment before each cycle

Inotuzumab Ozogamicin (Besylomi® / Besponsa®)

Parameter	Details
MOA	Anti-CD22 antibody conjugated to calicheamicin (DNA-damaging payload) — targeted delivery to CD22+ B blasts
Indication	R/R B-ALL (adults); bridge to allogeneic HCT
Dose	Cycle 1: 0.8 mg/m² day 1 + 0.5 mg/m² days 8 & 15 (total 1.8 mg/m²/cycle). Subsequent cycles (CR): 0.5 mg/m² days 1, 8, 15 (total 1.5 mg/m²/cycle). 28-day cycles.
Cytoreduction threshold	Consider cytoreduction if absolute blast count ≥10,000/µL (use hydroxyurea or steroids + vincristine)
SOS/VOD Risk	CRITICAL: Monitor bilirubin and liver enzymes closely. Highest risk: prior allogeneic HCT, >2 cycles, double-alkylator conditioning pre-HCT. Avoid double-alkylator conditioning. Consider ursodiol prophylaxis.
SOS Treatment	Defibrotide for inotuzumab-related SOS/VOD (per NCCN ALL-C)
Myelosuppression	Common; institutional antimicrobial prophylaxis recommended
Key Labs	LFTs, bilirubin (watch closely for SOS), CBC, coagulation
Post-HCT planning	Inform transplant team of prior InO exposure — avoid double alkylator conditioning

Asparaginase Products

Product	Source	Dose / Route	Half-Life	Key Notes
Pegaspargase (Oncaspar®)	E. coli (PEGylated)	2500 IU/m² IM or IV (vial = 3750 IU); DOSE CAPPED AT 1 VIAL (3750 IU)	5–7 days (PEGylation extends activity)	Preferred first-line asparaginase. IV route preferred (NCCN). TDM recommended with low-grade reactions.
Calaspargase pegol-mknl (Asparlas®)	E. coli (PEGylated; different PEG linkage)	2500 IU/m² IV; dose capped at 1 vial (3750 IU)	Longer than pegaspargase (~26 days)	Used in patients aged ≤21 yrs as substitution for more sustained activity (per v1.2026). IV only.
ERW-rywn (Rylaze®)	Erwinia chrysanthemi (recombinant)	25 mg/m² IM Mon/Wed + 50 mg/m² IM Fri × 2 weeks (new v1.2026 schedule)	~16 hrs (IM)	For E. coli asparaginase hypersensitivity. More frequent dosing required. IM injection only. Monitor nadir activity.

Asparaginase Toxicity Management (NCCN ALL-C 3–5 of 6)

Toxicity	Grade/Threshold	NCCN Recommended Action
Hypersensitivity / Allergy	Grade 1–2 (rash, flushing, urticaria, fever <38°C without bronchospasm)	Continue with premedication (hydrocortisone, famotidine, diphenhydramine/cetirizine, acetaminophen). TDM highly recommended if premedicating (masks neutralizing antibody reaction).
Anaphylaxis / Grade 3–4 Allergic Reaction	Grade 3 or 4 systemic	PERMANENTLY DISCONTINUE causative asparaginase. Switch to ERW-rywn.
Hyperglycemia	Grade 3 or higher	Hold asparaginase AND steroids until blood glucose regulated with insulin. Resume after control.
Hypertriglyceridemia	Grade 4	Hold asparaginase until normalized. Resume after normalization.
Pancreatitis	Clinical or Grade ≥2	Hold asparaginase. Assess severity. For severe or hemorrhagic pancreatitis: likely permanent discontinuation. For mild: may resume after full resolution (protocol-dependent).
Hepatotoxicity — Direct Bilirubin	≤3.0 mg/dL: Continue 3.1–5.0 mg/dL: Hold until <2.0, then resume >5.0 mg/dL: Hold or discontinue; resume if <2.0 with dose reduction + close monitoring	Monitor LFTs and bilirubin before each dose
Hepatotoxicity — AST/ALT	Grade 3: Hold until Grade 1, then resume Grade 4: Hold until Grade 1 (if ≤1 week: resume; if >1 week: discontinue or very close monitoring)	Close monitoring essential
Coagulopathy / Thrombosis	Fibrinogen <50–100 mg/dL; AT deficiency; symptomatic DVT/PE	Replace fibrinogen (cryoprecipitate), AT (AT concentrate/FFP). Anticoagulation per institutional protocol. Consider primary VTE prophylaxis.
Cerebral sinus thrombosis	Neurological symptoms, headache	MRV/MRA imaging. Anticoagulation typically indicated. Multidisciplinary management.

CAR-T Cell Therapy

Agent	Indication	Lymphodepletion	Key Toxicities & Management
Tisagenlecleucel (Kymriah®)	Pediatric/AYA ≤25 yrs, R/R B-ALL	Fludarabine 25 mg/m²/day × 3 days + cyclophosphamide 900 mg/m² × 1 day (days −4 to −2)	CRS (tocilizumab ± steroids), ICANS (steroids, levetiracetam), prolonged cytopenias, B-cell aplasia (IVIG replacement), infections
Brexucabtagene autoleucel (Tecartus®)	Adults with R/R B-ALL	Fludarabine 30 mg/m²/day × 3 + cyclophosphamide 500 mg/m²/day × 3	CRS, ICANS, cytopenias, HLH/MAS, infections
Obecabtagene autoleucel (Aucatzyl®)	Adults with R/R B-ALL	Protocol-specified lymphodepletion	CRS, ICANS, cytopenias

MEASURABLE (MINIMAL) RESIDUAL DISEASE (MRD) (NCCN ALL-F)

12.1 MRD Assessment Methods

Method	Sensitivity	Application
Multiparameter flow cytometry (MFC)	10⁻⁴	Standard method; widely available; requires baseline for leukemia-specific phenotype
RT-PCR (BCR::ABL1 quantitative)	10⁻⁵–10⁻⁶	Ph+ ALL only; gold standard for molecular MRD; p190 vs p210 must be tracked consistently
NGS-based (Ig/TCR clonotyping)	10⁻⁶	PREFERRED FDA-approved method (NCCN preferred) — detects clonal Ig/TCR rearrangements; does NOT require patient-specific primers. E.g., Adaptive clonoSEQ
ASO-PCR	10⁻⁵	Requires patient-specific primers from baseline sample; highly sensitive but labor-intensive

12.2 MRD Interpretation & Clinical Action

• Preferred MRD method (NCCN v1.2026): FDA-approved NGS-based assay for Ig/TCR rearrangements, if available.
• MRD+ after induction: STRONG indication for intensification and/or allogeneic HCT consideration.
• Increasing MRD frequency of monitoring: useful for molecular relapse or low-level disease; and for Ph+ ALL patients discontinuing TKI.
• BCR::ABL1 qPCR positivity: may reflect persistence in myeloid compartment (residual CML clone) — not necessarily ALL relapse. Flow-sort myeloid vs. lymphoid cells for FISH/NGS to clarify when feasible.
• MRD negativity before allogeneic HCT: associated with better post-HCT outcomes. Therapy aimed at eliminating MRD before HCT is preferred.
• Referral: Given complexity of MRD management — NCCN recommends referral to/consultation with center with expertise for any ALL patient with MRD positivity.

🔑 Clinical Pearls — MRD MRD assessment time points MATTER — different regimens have different optimal MRD assessment time points (end of induction, after consolidation blocks). Always refer to the specific protocol being used.NGS MRD is now the PREFERRED method per NCCN v1.2026 — it uses broad primers (no patient-specific setup) and achieves 10⁻⁶ sensitivity.Flow cytometry MRD: requires a baseline (diagnostic) sample to characterize the leukemia-specific immunophenotype for subsequent comparison. If baseline was not sent, sensitivity and accuracy decrease.MRD+ post-induction in Ph+ ALL: ABL1 KD mutation testing may be less sensitive at low disease burden — do not rely solely on mutation testing when MRD is minimal.

13. RESPONSE ASSESSMENT CRITERIA (NCCN ALL-E)

Response	Definition
Complete Remission (CR)	<5% blasts in BM by morphology + no extramedullary disease + peripheral blood count recovery (ANC ≥1.0×10⁹/L, platelets ≥100×10⁹/L)
CR with Incomplete Hematologic Recovery (CRi)	<5% blasts + no extramedullary disease + incomplete peripheral blood count recovery (ANC <1.0 or Plt <100)
CR with Partial Hematologic Recovery (CRh)	<5% blasts + no extramedullary disease + partial count recovery (ANC ≥0.5, Plt ≥50)
Morphologic Leukemia-Free State (MLFS)	<5% blasts in BM with indeterminate peripheral blood recovery (e.g., in aplasia post-therapy)
No Response (NR)	≥5% blasts in BM or persistent extramedullary disease
Progressive Disease (PD)	Increasing blast % or new extramedullary disease
MRD-negative CR	CR criteria met + MRD below detection threshold by sensitive method (NGS/PCR/flow)

Count recovery per protocol is recommended BEFORE transitioning to post-remission therapy, even in the presence of MRD negativity. If count recovery is not achieved, assess for myelosuppression secondary to TKI and consider dose reduction.

14. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALL-G)

14.1 Indications for Allogeneic HCT in ALL

• Poor-risk cytogenetics (hypodiploid, KMT2A-rearranged, Ph+ with IKZF1plus, complex karyotype, Ph-like).
• MRD positivity after induction/consolidation (slow/incomplete MRD clearance).
• ETP-ALL with MRD positivity post-induction.
• CR2 or beyond (relapsed ALL achieving second remission).
• Ph+ ALL: Consider in MRD+ patients; patients ≤21 yrs achieving MRD negativity may not need HCT (data support chemo + TKI).
• Early transplant evaluation and donor search: NCCN strongly recommends consideration at diagnosis for all high-risk patients (updated ALL-3 v1.2026).

14.2 Post-HCT Considerations

• Post-HCT TKI maintenance: Standard for Ph+ ALL after allogeneic HCT. Typically dasatinib or ponatinib.
• Post-HCT MRD monitoring: Increased frequency monitoring (especially for Ph+ ALL patients discontinuing TKI).
• Germline testing: Hereditary ALL predisposition variants may impact HCT DONOR selection — expeditious germline testing before HCT is important (updated ALL-A v1.2026).
• Defibrotide: available for SOS/VOD (can occur after HCT, especially in prior InO-treated patients).

⚠️ CRITICAL PHARMACIST WATCHOUT: Pre-HCT Planning in ALL Inotuzumab ozogamicin history → flag at tumor board before HCT conditioning planning. DOUBLE ALKYLATOR CONDITIONING STRONGLY DISCOURAGED due to catastrophic SOS/VOD risk.CAR T-cell manufacturing logistics: coordinate with apheresis, pharmacy, and transplant team. Bridging therapy must be carefully selected to avoid compromising CAR T fitness.Germline testing BEFORE HCT: if pathogenic germline variant identified (e.g., TP53, PAX5, ETV6, RUNX1) → may affect donor selection (avoid donor with same variant in related donors).Post-HCT TKI: ensure TKI is ordered and insurance-approved before discharge. Engraftment + TKI = standard of care in Ph+ ALL.

15. PRINCIPLES OF SUPPORTIVE CARE (NCCN ALL-C)

15.1 Antiemesis

• Highly emetogenic chemotherapy (HEC: e.g., high-dose cyclophosphamide, high-dose cytarabine, cisplatin combinations): 3–4 drug prophylaxis (5HT3 RA + NK1 RA + dexamethasone + olanzapine).
• Moderately emetogenic (MEC): 5HT3 RA + dexamethasone ± NK1 RA (per institutional protocol).
• Asparaginase: low emetogenic potential — premed as needed.
• Methotrexate (high-dose): MEC category — 5HT3 RA + dexamethasone.
• Note: Dexamethasone as antiemetic must be carefully considered when steroids are already part of ALL regimen (avoid duplication/excess steroid).

15.2 Infection Prophylaxis (NCCN ALL-C)

Infection Type	Recommended Prophylaxis	Key Notes
PCP (Pneumocystis jirovecii)	TMP-SMX DS PO 3×/week (preferred) OR dapsone 100 mg/day OR inhaled pentamidine 300 mg q4 weeks OR atovaquone 1500 mg/day	Continue throughout immunosuppressive therapy. TMP-SMX: check G6PD before dapsone. Dapsone: avoid with G6PD deficiency.
Fungal (Antifungal prophylaxis)	Fluconazole 400 mg PO daily (prophylaxis during neutropenia) OR posaconazole 300 mg PO/IV daily (for high-risk: ≥7d neutropenia expected)	Fluconazole: CYP2C9/3A4 interactions (major). Posaconazole: CYP3A4 strong inhibitor — TKI interactions! Voriconazole: strong CYP3A4 inhibitor — significant dasatinib/ponatinib interaction. Check all drug interactions.
HSV/VZV prophylaxis	Acyclovir 400 mg PO BID OR valacyclovir 500 mg PO daily	Continue for duration of immunosuppression and 3–6 months post-completion
HBV reactivation	Screen all patients: HBsAg, anti-HBc, anti-HBs. If HBsAg+ or anti-HBc+: entecavir or tenofovir prophylaxis	Especially important with rituximab. Prophylaxis continues 6–12 months post-therapy.
CMV (post-HCT)	Letermovir prophylaxis (CMV-seropositive recipients), or preemptive monitoring/treatment	Post-HCT management per transplant protocol
Bacterial (during aplasia)	Fluoroquinolone prophylaxis (levofloxacin/ciprofloxacin) during prolonged neutropenia per institutional protocol	Risk of fluoroquinolone resistance development with prolonged use

⚠️ PHARMACIST WATCHOUT: Drug Interactions in ALL Prophylaxis + TKIs Posaconazole/voriconazole + dasatinib/nilotinib/ponatinib: MAJOR interaction — azole antifungals are potent CYP3A4 inhibitors → significantly increase TKI levels → toxicity. Flag and notify oncology team. Consider dose reduction of TKI per PKI-specific labeling, or switch to fluconazole (weaker CYP3A4 effect).Fluconazole + nilotinib: fluconazole significantly inhibits CYP2C9 and CYP3A4 → may increase nilotinib exposure + QTc prolongation risk. Monitor ECG.TMP-SMX: can cause myelosuppression (folate antagonism) — may confound maintenance myelosuppression from MTX/6-MP. Monitor CBC.Acyclovir: dose adjust for renal impairment. During high-dose MTX cycles, ensure adequate hydration to prevent both MTX and acyclovir nephrotoxicity.

15.3 Tumor Lysis Syndrome (TLS) Prophylaxis

• High TLS risk: ALL with high WBC or bulky disease.
• Allopurinol 300 mg/day PO starting 24–48h before chemotherapy (first-line for prevention).
• Rasburicase (recombinant urate oxidase): Use for high-risk patients or established TLS (converts uric acid to allantois). CONTRAINDICATED in G6PD deficiency (hemolytic anemia risk). Check G6PD before use.
• IV hydration: 2–3 L/m²/day. Avoid alkalinization (unnecessary with rasburicase; may worsen calcium phosphate precipitation).
• Monitor: uric acid, K⁺, Ca²⁺, PO₄, creatinine q4–8h during high-risk period.
• Urinary alkalinization: historically used with allopurinol but generally not recommended with rasburicase. Avoid in hyperphosphatemia (Ca-phosphate precipitation risk).

15.4 Corticosteroid Toxicity Management

• Hyperglycemia (acute): Frequent blood glucose monitoring. Insulin sliding scale/correction doses. If dexamethasone-based: hyperglycemia more pronounced vs. prednisone.
• GI protection: PPI (omeprazole/pantoprazole) or H2 blocker for steroid-induced ulcer prophylaxis during induction.
• Avascular necrosis (AVN): Long-term complication of cumulative steroid exposure — especially in AYA. Symptom monitoring, DEXA scan, bone density.
• Mood/behavioral changes (neuropsychiatric): Common in pediatric/AYA population. Inform patients and families.
• Osteoporosis prophylaxis: Calcium + vitamin D during prolonged steroid therapy.

15.5 Nutritional Support

• Enteral or parenteral support: Consider for >10% weight loss.
• Asparaginase-related hypertriglyceridemia: Dietary fat restriction + pharmacological management (fibrates/omega-3s) as needed.

15.6 Growth Factor Support

• G-CSF (filgrastim/pegfilgrastim): Use per institutional protocol for severe or prolonged neutropenia after consolidation or maintenance cycles. Avoid during acute induction (may stimulate leukemic progenitors in some ALL subtypes — caution). Standard use post-intensification consolidation cycles.
• Pegfilgrastim: avoid if next cycle is within 14 days of administration.
• Erythropoiesis-stimulating agents (ESA): NOT routinely used in ALL given active disease/therapy.

16. ALL PHARMACOTHERAPY — QUICK REFERENCE DRUG TABLE

Medication (Brand)	Class / Subclass / MOA	Clinical Pearls / Key Side Effects / Counseling Points
Vincristine (Vincasar®)	Vinca alkaloid / Antimitotic — binds tubulin → mitotic arrest	2 mg IV CAP (adults). Vesicant — central line required. Peripheral neuropathy (dose-limiting; assess at every visit). Constipation — stool softener prophylaxis required. FATAL if given IT — multiple patient safety steps required. Never refrigerate.
Dexamethasone / Prednisone	Corticosteroid / Induces lymphoblast apoptosis via GR	Dexamethasone preferred in AYA (greater CNS penetration, less AVN at equivalent anti-tumor doses in some studies). Monitor glucose q6h during pulse. GI prophylaxis required. Taper after prolonged use to avoid adrenal insufficiency.
Daunorubicin (Cerubidine®) / Doxorubicin	Anthracycline / Intercalates DNA, inhibits topoisomerase II, generates ROS	Cumulative lifetime dose limits (doxorubicin: ~450–550 mg/m²; daunorubicin: ~550 mg/m²). Vesicant — extravasation = dexrazoxane antidote. Cardiotoxicity: serial ECHO monitoring. Red urine (normal — counsel patient). Myelosuppression.
Cyclophosphamide (Cytoxan®)	Alkylating agent / Cross-links DNA strands	MESNA required (hemorrhagic cystitis prevention). Urine output monitoring. Hyponatremia risk (SIADH). Nausea: pre-medications. Alopecia. Gonadotoxicity.
Methotrexate (systemic HD)	Antifolate / Inhibits DHFR → impairs DNA synthesis	Leucovorin rescue CRITICAL (timing per protocol). Monitor MTX levels. Creatinine and urine pH monitoring. Alkalinize urine to pH >7 for excretion. Renal toxicity risk. Mucositis. Drug interactions: NSAIDs ↑ MTX toxicity (avoid).
Methotrexate (IT)	Same MOA; direct CNS delivery	Age-based flat dosing (NOT BSA-based for adults: 12 mg IT). Arachnoiditis (transient). Leucovorin rescue NOT routinely given after IT dose (unless protocol specifies). Never administer with liposomal IT cytarabine on same day without specific protocol guidance.
Cytarabine (Ara-C) — Standard	Pyrimidine analog / Inhibits DNA polymerase → chain termination	Myelosuppression dose-limiting. Low-dose (SC) vs. high-dose (IV) — different toxicities. High-dose: cerebellar toxicity, keratoconjunctivitis — steroid eye drops mandatory.
Cytarabine (Ara-C) — High-Dose	Same MOA; higher drug exposure	Steroid eye drops (prednisolone 1% BID × 48h after last HD Ara-C dose). Dose reduce to 1 g/m² for age >60 or renal impairment. Cerebellar toxicity (ataxia, nystagmus) → HOLD immediately if suspected.
6-Mercaptopurine (6-MP / Purinethol®)	Thiopurine / Inhibits purine synthesis → DNA incorporation → cell death	TPMT/NUDT15 genotype BEFORE starting. Take on EMPTY STOMACH. Allopurinol interaction — reduce dose by 75% if co-prescribed. Monitor CBC/LFTs q2–4wk. Hepatotoxicity, cholestasis. Azathioprine/6-MP duplication check.
Pegaspargase (Oncaspar®)	Asparaginase enzyme / Depletes circulating asparagine → protein synthesis inhibition in lymphoblasts	IV route preferred. Cap at 1 vial (3750 IU). Allergy screening before each dose. TDM recommended. Coagulation panel before each dose. Pancreatitis, hepatotoxicity, hyperglycemia, thrombosis/bleeding monitoring. See toxicity table.
Dasatinib (Sprycel®)	2nd-gen BCR::ABL1 TKI + SRC kinase inhibition	100 mg PO daily for ALL. QTc monitoring. Pleural effusion (may require diuretics or dose hold). CYP3A4 substrate — MAJOR azole interactions. Take without regard to food (avoid antacids). BMS within 2h of administration.
Ponatinib (Iclusig®)	3rd-gen BCR::ABL1 TKI / STAMP inhibitor (pan-BCR::ABL1)	Active against T315I. Arterial occlusive events (ATE) — screen CV risk factors; dose-reduce to 15 mg once MRD negative. Hypertension, hepatotoxicity, pancreatitis. CYP3A4 substrate. Dose starting point: 30–45 mg/day → reduce per response.
Nilotinib (Tasigna®)	2nd-gen BCR::ABL1 TKI	QTc prolongation — EKG before dosing and monitoring. Must be taken FASTING (2h before, 1h after food — food increases absorption and QTc risk). CYP3A4 substrate. Hyperglycemia, rash, pancreatitis.
Asciminib (Scemblix®)	STAMP inhibitor (BCR::ABL1 kinase + myristate pocket)	Category 2B in ALL (multiple TKI intolerance). Active against T315I (higher dose required: 200 mg BID). QTc monitoring. CYP3A4 substrate.
Blinatumomab (BLINCYTO®)	BiTE antibody construct / CD19×CD3 bispecific T-cell engager	Continuous IV infusion (ambulatory pump). Dexamethasone premeds. CRS/cytokine release monitoring. Neurological toxicity (confusion, seizures, aphasia — hold, restart at 9 mcg). Down syndrome: antiepileptic prophylaxis. Cytoreduction if blasts ≥15,000/µL.
Inotuzumab Ozogamicin (Besylomi® / Besponsa®)	ADC / Anti-CD22 + calicheamicin payload	SOS/VOD risk (fatal). Avoid double-alkylator conditioning pre-HCT. Monitor bilirubin closely. Ursodiol prophylaxis. Defibrotide for SOS. Cytoreduction if blasts ≥10,000/µL.
Nelarabine (Arranon®)	Purine nucleoside analog / Ara-G prodrug → T-cell selective cytotoxicity	T-ALL specific. Neurotoxicity (somnolence, encephalopathy, peripheral neuropathy, Guillain-Barré-like) — HOLD for Grade ≥2. Adequate hydration. Never IT. Myelosuppression.
Rituximab (Rituxan®)	Anti-CD20 monoclonal antibody / ADCC + complement-mediated cytotoxicity	CD20+ B-ALL (>20%). Infusion reactions — premedicate (acetaminophen + diphenhydramine). HBV reactivation risk — screen and prophylax. PML risk (progressive multifocal leukoencephalopathy) — rare. Neutropenia.
Tisagenlecleucel (Kymriah®)	CD19-directed CAR T-cell therapy (autologous)	CRS (tocilizumab), ICANS (steroids + levetiracetam), prolonged cytopenias, B-cell aplasia (IVIG). Minimize pre-infusion steroids. Manufacturing 3–4 weeks. For patients ≤25 yrs.
Revumenib (Revuforj®)	Menin inhibitor / Blocks MLL-menin interaction → differentiation	KMT2A-rearranged ALL. Differentiation syndrome: fever, dyspnea, edema, pleural/pericardial effusion → dexamethasone. QTc monitoring. CYP3A4 substrate.
Venetoclax (Venclexta®)	BCL-2 inhibitor / Restores apoptosis in BCL-2-overexpressing cells	Emerging in R/R ALL (combinations). TLS risk on initiation — ramp-up required (oncology team to follow heme TLS protocol). CYP3A4 substrate — MAJOR azole interactions. GI toxicity.
Defibrotide (Defitelio®)	Fibrinolytic/cytoprotective agent / Restores thrombofibrinolytic balance endothelially	ONLY FDA-approved treatment for SOS/VOD. 6.25 mg/kg IV q6h (25 mg/kg/day) × minimum 21 days. Monitor: bleeding, hypotension. Contraindicated with systemic anticoagulation (relative). Renal and hepatic dose adjustments not required.
Hydroxyurea (Hydrea®)	Ribonucleotide reductase inhibitor / Cytoreduction	Used for initial cytoreduction in hyperleukocytosis or pre-blinatumomab/InO cytoreduction. Not definitive therapy. Monitor CBC closely. Short half-life.

17. KEY CLINICAL TRIALS — BRIEF SUMMARY

Trial	Population	Intervention vs. Comparator	Key Results / Outcome
CALGB 10403	AYA 17–39 yrs, Ph− ALL	Pediatric-inspired (COG AALL0434 regimen) vs historical adult regimens	5-yr OS 73% vs 46% (historical adult). Demonstrated superiority of peds-inspired approach in AYA. Established benchmark.
GRAALL-2005 (Rituximab)	Adults ≤60 yrs, CD20+ Ph− B-ALL	Rituximab + chemotherapy vs chemotherapy alone	Improved event-free survival with rituximab (4-yr EFS 65% vs 52%). Rituximab now standard in CD20+ B-ALL.
BLAST Trial (Blinatumomab MRD+)	Adults with MRD+ B-ALL after consolidation	Blinatumomab (4 cycles) as consolidation	78% achieved MRD negativity. Improved OS. Established blinatumomab in MRD+ B-ALL.
INO-VATE (Inotuzumab)	Adults R/R B-ALL	Inotuzumab ozogamicin vs standard salvage chemotherapy	CR/CRi 80.7% vs 29.4%. Improved OS. Established InO in R/R B-ALL. High SOS/VOD risk post-HCT noted.
ELIANA (Tisagenlecleucel)	Pediatric/AYA ≤25 yrs R/R B-ALL	Tisagenlecleucel (single infusion)	Overall remission rate 81%. 12-month EFS 50%. Established CAR T-cell in ≤25 yrs R/R B-ALL.
ZUMA-3 (Brexucabtagene)	Adults R/R B-ALL	Brexucabtagene autoleucel (single infusion)	Overall remission rate 71%. MRD negativity in 85% of responders. Established in adult R/R B-ALL.
PhALLCON (Ponatinib + chemotherapy)	Adults Ph+ ALL	Ponatinib + reduced-intensity chemotherapy vs imatinib + chemotherapy	Improved MRD negativity and survival with ponatinib. Ponatinib now preferred TKI over imatinib. (Jabbour et al., JAMA 2024 — cited in NCCN v1.2026)
COG AALL0031 (Dasatinib in peds Ph+)	Children/AYA Ph+ ALL	Chemotherapy + dasatinib (continuous)	Excellent outcomes without HCT in MRD− patients. Established TKI + chemo without mandatory HCT for MRD− ≤21 yrs.
AALL1231 (Nelarabine in T-ALL)	AYA/pediatric T-ALL	Backbone + nelarabine vs backbone alone	Improved DFS in standard-risk T-ALL with nelarabine addition. Supports nelarabine use in frontline T-ALL.
AALL1931 (ERW-rywn IM schedule)	Pediatric/AYA ALL, E. coli asparaginase hypersensitivity	ERW-rywn new IM schedule (25 mg/m² Mon/Wed, 50 mg/m² Fri × 2 wks)	Positive risk:benefit ratio. Supports new IM dosing schedule — incorporated in NCCN v1.2026.

18. CRITICAL PHARMACIST WATCHOUTS — CONSOLIDATED

18.1 Chemotherapy Order Verification

• VINCRISTINE: Absolute cap = 2 mg IV. Check every order. Verify it is NOT ordered for IT administration (fatal error). Use vincristine-specific bags/overwraps per USP <797> and ISMP guidelines.
• HIGH-DOSE MTX: Leucovorin rescue timing is critical. MTX level monitoring at 24h, 48h, 72h post-infusion. Adequate urine alkalinization (pH >7) before and during infusion.
• HIGH-DOSE ARA-C (≥1 g/m²): Steroid eye drops order MUST be placed (prednisolone 1% or equivalent BID). Reduce to 1 g/m² for age >60 or CrCl <60 mL/min. Cerebellar symptom assessment.
• PEGASPARGASE: Verify dose does not exceed 1 vial (3750 IU). IV route preferred. Coagulation panel before each dose. Premedication orders if needed.
• CYCLOPHOSPHAMIDE: MESNA co-order verification at every cycle. Urine output monitoring every 4h during administration.
• BLINATUMOMAB: Dexamethasone premedication before cycle start and dose step-up. Continuous pump operation — check IV line integrity, pump programming, stabilizer compatibility.

18.2 Lab Monitoring Cutoffs (General Guidance — Always Verify per Protocol)

Lab Parameter	Typical Hold/Action Threshold	Context
ANC	<500–1000/µL (hold myelosuppressive therapy/reduce dose per protocol)	Maintenance 6-MP/MTX: target ANC 1.5–3.0×10⁹/L for dose adjustment
Platelets	<50,000/µL (hold consolidation/maintenance agents typically)	Protocol-specific; some regimens hold at <75,000
Creatinine / CrCl	CrCl <50: reduce/hold HD methotrexate, cytarabine adjustments	Check before each HD MTX cycle; methotrexate requires adequate renal clearance
Total Bilirubin	>3× ULN: hold asparaginase (>3.1 mg/dL), hold/reduce vincristine (>3.0 mg/dL hepatic)	Asparaginase-specific thresholds as per NCCN ALL-C
Direct Bilirubin	>3.0 mg/dL: continue Aspar | 3.1–5.0: hold until <2.0 | >5.0: hold or discontinue	SOS/VOD monitoring with InO
AST/ALT	Grade 3 (>5× ULN): hold asparaginase/6-MP | Grade 4 (>20× ULN): discontinue consideration	LFT monitoring each cycle
Fibrinogen	<100 mg/dL: consider cryoprecipitate replacement (especially with asparaginase)	DIC/coagulopathy monitoring
Uric Acid	>8 mg/dL (or >10 mg/dL in high-risk): rasburicase | otherwise allopurinol	TLS monitoring q8h during induction
Blood Glucose	>250–300 mg/dL Grade 3: hold asparaginase + steroids until controlled	Insulin management with endocrinology/pharmacy
Amylase/Lipase	Symptomatic elevation (Grade ≥2): hold asparaginase. Asymptomatic: monitor closely, do not auto-hold	Differentiate asymptomatic elevation from true pancreatitis
QTc	>480–500 ms: review all QTc-prolonging drugs; consider TKI hold/switch (nilotinib, ponatinib, asciminib)	EKG monitoring with QTc-prolonging TKIs
ECHO/LVEF	<50% or drop ≥10% from baseline: hold anthracyclines; cardiology consult	Serial monitoring during ALL therapy

18.3 Critical Drug Interactions

Drug Pair	Severity	Mechanism & Management
6-MP + Allopurinol	CONTRAINDICATED / Severe	Allopurinol inhibits xanthine oxidase → 6-MP accumulates → fatal myelosuppression. Reduce 6-MP dose by 75% if unavoidable. Prefer febuxostat (enzyme not inhibited by febuxostat) OR avoid combination.
Azole antifungals (Posaconazole/Voriconazole) + Dasatinib/Nilotinib/Ponatinib	Major	Strong CYP3A4 inhibition → ↑ TKI exposure → toxicity. Use fluconazole or micafungin if possible. If azole required: reduce TKI dose per labeling/pharmacist guidance.
Methotrexate + NSAIDs	Major	NSAIDs ↓ renal excretion of MTX → MTX toxicity (mucositis, nephrotoxicity, myelosuppression). AVOID NSAIDs during HD MTX cycles.
Methotrexate + Trimethoprim (TMP-SMX)	Major	Additive folate antagonism → myelosuppression, mucositis. If TMP-SMX is PCP prophylaxis: hold during HD MTX cycles; restart after MTX clearance.
Dasatinib + Antacids (aluminum/magnesium-containing)	Moderate	Antacids ↑ gastric pH → ↓ dasatinib absorption. Separate dasatinib and antacids by ≥2 hours.
Nilotinib + Food	Major (pharmacokinetic)	Food ↑ nilotinib absorption by 80–112% → ↑ QTc + toxicity. Must take FASTING (2h before, 1h after meals).
Venetoclax + Strong CYP3A4 inhibitors (azoles)	Major	↑ Venetoclax exposure significantly → severe TLS/myelosuppression risk. Dose reduce venetoclax by 75% with strong inhibitors.
Cyclophosphamide + QTc-prolonging agents	Moderate	Additive risk — screen medication list for QTc-prolonging drugs.
Corticosteroids + Vaccines (live)	Contraindicated during immunosuppression	Avoid live vaccines during active chemotherapy. MMR, varicella, zoster live vaccines contraindicated.

19. SPECIAL POPULATIONS

19.1 Adults ≥65 Years or Substantial Comorbidities (NCCN ALL-D 3 of 29)

• Reduced-intensity regimens preferred: moderate-intensity multiagent, steroids + TKI.
• Avoid high-dose cytarabine (≥3 g/m²) — use 1 g/m²; omit or reduce asparaginase.
• TKI monotherapy (steroids + TKI): may be appropriate as induction for very frail/elderly Ph+ patients; CR rates reasonable.
• CNS prophylaxis: liposomal cytarabine IT may be an option in older patients (reduces treatment frequency).
• Anthracycline dose reduction for cardiac comorbidities — baseline ECHO essential.
• G-CSF support: more liberal use in elderly.
• Allogeneic HCT: consider for appropriate fit elderly individuals achieving remission (updated v1.2026).
• Safety of full-intensity R/R salvage regimens in adults ≥65 yrs not established — individualize.

19.2 AYA Patients (15–39 years)

• NCCN defines AYA as 15–39 years (not a firm cutoff — some regimens not tested across full range).
• Pediatric-inspired regimens (CALGB 10403, COG-based): significantly superior OS vs traditional adult regimens.
• Higher asparaginase tolerance vs. older adults — core component of AYA regimens.
• Fertility preservation: discuss gonadotoxicity before initiation. Refer to reproductive endocrinology when feasible. Sperm banking, oocyte/embryo cryopreservation.
• Long-term toxicities: avascular necrosis (cumulative steroids), neurotoxicity, cardiotoxicity (anthracyclines), secondary malignancies (alkylators).
• Psychosocial: refer to AYA oncology program/NCCN AYA guidelines.

19.3 Ph-Like (BCR::ABL1-Like) ALL

• ~20–25% of AYA/adult B-ALL — BCR::ABL1 NEGATIVE but gene expression profile similar to Ph+ ALL.
• Must use comprehensive NGS for identification — not detectable by standard FISH.
• Actionable fusions:
  • JAK-STAT pathway (CRLF2r, JAK1/2r, EPORr): ruxolitinib (JAK1/2 inhibitor) sensitivity. Add ruxolitinib to induction/consolidation (clinical trial context preferred).
  • ABL-class fusions (ABL1r, ABL2r, PDGFRAr, PDGFRBr, FGFRr): TKI-sensitive — dasatinib or ponatinib can be added.
• Currently, NCCN recommends clinical trial enrollment for Ph-like ALL when possible.

19.4 Down Syndrome ALL

• Increased sensitivity to methotrexate and cytarabine → requires dose adjustments.
• Increased risk of infections and treatment-related toxicity.
• NEW v1.2026: Increased risk of seizures with blinatumomab in Down syndrome patients — antiepileptic prophylaxis SHOULD BE CONSIDERED.

20. SURVEILLANCE (NCCN ALL-7)

Time Point / Frequency	Recommended Assessments
During therapy (each cycle)	CBC with differential, CMP, LFTs, coagulation studies (esp. with asparaginase). MRD assessment per protocol time points. ECG for QTc-prolonging TKIs.
Post-induction CR	Bone marrow biopsy + MRD assessment. BCR::ABL1 qPCR (Ph+). Cytogenetics if needed.
End of consolidation	BM biopsy + MRD. Restaging imaging if extramedullary disease. Reassess HCT candidacy.
During maintenance	CBC q2–4 weeks (dose adjust 6-MP/MTX to target ANC). LFTs q1–3 months. MRD q3–6 months (protocol-dependent).
Post-therapy completion	CBC, LFTs, CMP q3 months × 2 yrs, then annually. Long-term: annual ECHO (anthracycline exposure), DEXA scan (steroids), neurocognitive assessment. Late toxicity surveillance per COG LTFU guidelines.
Ph+ ALL off TKI	Increased MRD frequency monitoring — monthly × 3 months, then q3 months.
Relapse surveillance	Any new cytopenias, symptoms → prompt BM evaluation.

21. KEY PATIENT COUNSELING POINTS

Induction Phase Counseling

• Explain treatment phases (induction → consolidation → maintenance) and overall duration (~2.5–3 years).
• Infection precautions during neutropenia: hand hygiene, avoid crowds/sick contacts, no live vaccines.
• When to call/go to ER: fever >38°C (100.4°F) — IMMEDIATE — do not wait.
• Blood transfusion support: may need platelet/RBC transfusions during aplasia.
• Hair loss (alopecia): temporary; common with anthracyclines and cyclophosphamide.
• Contraception: avoid pregnancy during therapy (teratogenic drugs). Discuss fertility preservation BEFORE starting.

Maintenance Phase Counseling

• 6-MP: Take on EMPTY STOMACH at BEDTIME. Avoid dairy within 1 hour. Do not take with allopurinol without provider guidance.
• Weekly oral methotrexate: Take same day each week. Avoid alcohol (additive hepatotoxicity). Use reliable contraception.
• Continue PCP prophylaxis (TMP-SMX) throughout entire maintenance.
• Report: fatigue, unusual bruising/bleeding, jaundice, severe mouth sores, nausea/vomiting.

TKI Counseling (Ph+ B-ALL)

• Dasatinib: Take once daily; food does not significantly affect absorption. Avoid antacids within 2h. Monitor for dyspnea/peripheral edema (pleural effusion). Report immediately.
• Nilotinib: Take FASTING (2h before, 1h after meals). Strict adherence — food significantly increases exposure and QTc risk.
• Ponatinib: Once daily with or without food. Report chest pain, stroke symptoms (arterial events), jaundice (hepatotoxicity).
• Missed dose: do NOT double-dose. Take as soon as remembered if within same day; skip if close to next dose.
• TKIs interact with many OTC drugs and supplements — review ALL medications (including herbal/supplements) with pharmacist.

22. CONSOLIDATED CLINICAL PEARLS — PHARMACIST EDITION

#	Domain	Clinical Pearl
1	Diagnosis	ETV6::RUNX1 is CRYPTIC by karyotype — always verify with FISH/PCR. Missing it changes risk stratification.
2	Diagnosis	BCR::ABL1 transcript type (p190 vs p210) matters for MRD monitoring — track consistently throughout therapy.
3	Risk Strat.	Near-haploid cells can DOUBLE and appear hyperdiploid — confirm with SNP array. Misclassification = under-treatment of poor-risk disease.
4	Risk Strat.	Ph-like ALL is actionable — MUST identify JAK-STAT vs ABL-class fusion for targeted therapy. NGS is required.
5	Ph+ ALL	Imatinib in frontline Ph+ ALL: RESTRICTED to patients intolerant of broader TKIs (per NCCN v1.2026). Dasatinib or ponatinib preferred.
6	Ph+ ALL	ABL1 KD mutation testing is less sensitive at minimal disease burden — interpret cautiously when MRD is low.
7	Ph+ ALL	Blinatumomab + TKI is now PREFERRED in consolidation for BOTH MRD+ AND MRD− Ph+ B-ALL (if not previously used).
8	Asparaginase	Dose CAP: 1 vial (3750 IU) regardless of BSA. Flag any orders exceeding this.
9	Asparaginase	TDM is HIGHLY RECOMMENDED when premedicating — premedication masks neutralizing antibodies. Target activity >0.1 IU/mL.
10	Asparaginase	Anticoagulation prophylaxis should be CONSIDERED with asparaginase — depletes fibrinogen, AT, protein C/S.
11	6-MP	TPMT/NUDT15 genotyping BEFORE starting 6-MP — poor metabolizers have fatal myelosuppression risk at standard doses.
12	6-MP	Take on EMPTY STOMACH at bedtime. Allopurinol interaction is SEVERE — reduce 6-MP by 75% if co-prescribed.
13	HD MTX	Leucovorin rescue timing is critical. NSAIDs and TMP-SMX increase MTX toxicity — HOLD during HD MTX cycles.
14	HD Ara-C	Steroid eye drops are NON-NEGOTIABLE with high-dose cytarabine. Place order proactively.
15	InO	SOS/VOD is life-threatening post-InO + allogeneic HCT. Double-alkylator conditioning STRONGLY DISCOURAGED. Flag at HCT planning.
16	Blinatumomab	Down syndrome patients: antiepileptic prophylaxis SHOULD BE CONSIDERED (NCCN v1.2026 update). Levetiracetam recommended.
17	CAR T-cell	Minimize corticosteroid use BEFORE CAR T-cell infusion — steroids impair CAR T expansion and efficacy.
18	Drug Interactions	Azole antifungals + TKIs = MAJOR CYP3A4 interaction. Alert the team and recommend dose adjustments or alternative antifungal.
19	TLS	Rasburicase CONTRAINDICATED in G6PD deficiency — check G6PD status before prescribing in high-TLS-risk patients.
20	MRD	NGS-based assay is now the PREFERRED MRD method per NCCN v1.2026. Understand the method used at your institution.
21	Supportive Care	Vincristine: NEVER in the refrigerator. NEVER IT. 2 mg CAP. Bowel regimen mandatory.
22	Supportive Care	PCP prophylaxis (TMP-SMX): Hold during HD MTX cycles — additive folate antagonism causes severe myelosuppression.
23	Transplant	Germline predisposition testing BEFORE HCT — pathogenic germline variants may affect DONOR selection.
24	Surveillance	Post-HCT TKI maintenance in Ph+ ALL: ensure TKI is ordered and approved at discharge — this is standard of care.
25	Counseling	Fever ≥38°C during neutropenia = MEDICAL EMERGENCY. Counsel every patient explicitly — do not wait, go directly to ER.

ABBREVIATIONS

Abbreviation	Meaning	Abbreviation	Meaning
ALL	Acute Lymphoblastic Leukemia	MRD	Measurable (Minimal) Residual Disease
AYA	Adolescent & Young Adult (15–39 yrs)	NGS	Next-Generation Sequencing
B-ALL	B-cell ALL	TKI	Tyrosine Kinase Inhibitor
T-ALL	T-cell ALL	HCT	Hematopoietic Cell Transplant
Ph+	Philadelphia chromosome-positive (BCR::ABL1+)	IT	Intrathecal
CR	Complete Remission	HD MTX	High-Dose Methotrexate
CRi	CR with Incomplete Hematologic Recovery	6-MP	6-Mercaptopurine
ETP	Early T-cell Precursor	PEG	Pegaspargase (Oncaspar®)
SOS/VOD	Sinusoidal Obstruction Syndrome / Veno-Occlusive Disease	InO	Inotuzumab Ozogamicin
CRS	Cytokine Release Syndrome	BiTE	Bispecific T-cell Engager
ICANS	Immune Effector Cell-Associated Neurotoxicity Syndrome	TDM	Therapeutic Drug Monitoring
FISH	Fluorescence In Situ Hybridization	MPAL	Mixed Phenotype Acute Leukemia
BM	Bone Marrow	LP	Lumbar Puncture
CSF	Cerebrospinal Fluid	TLS	Tumor Lysis Syndrome
TPMT	Thiopurine S-methyltransferase	NUDT15	Nudix hydrolase 15 (affects 6-MP metabolism)

— END OF GUIDE —

Based on NCCN Clinical Practice Guidelines in Oncology — Acute Lymphoblastic Leukemia, Version 1.2026 (April 8, 2026)

For educational and pharmacotherapy reference use only. Always verify with current guidelines and institutional protocols.